Merck KGaA readies new round of acquisitions and partnerships

Merck KGaA says it will take some of the billions it made off the sale of its generic business and go after new acquisitions. Executive Director Stefan Oschmann says that one area that the company plans to grow is in vaccines, though he isn't looking for any mega-mergers. He's also interested in biotech companies with late-stage development projects or promising research platforms. The company has a big appetite for deal-making. Merck inked 35 acquisitions and partnerships last year.

- here's the report on Merck from Javno

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.